News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,690 Results
Type
Article (42284)
Company Profile (436)
Press Release (670970)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (208753)
Career Advice (2021)
Deals (36011)
Drug Delivery (104)
Drug Development (83571)
Employer Resources (173)
FDA (16425)
Job Trends (15094)
News (352800)
Policy (33078)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50946)
ALS (92)
Alzheimer's disease (1424)
Antibody-drug conjugate (ADC) (135)
Approvals (16414)
Artificial intelligence (258)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (330)
Bladder cancer (68)
Brain cancer (26)
Breast cancer (279)
Cancer (2197)
Cardiovascular disease (182)
Career advice (1688)
Career pathing (30)
CAR-T (152)
Cell therapy (429)
Cervical cancer (19)
Clinical research (67692)
Collaboration (856)
Compensation (526)
Complete response letters (24)
COVID-19 (2643)
CRISPR (42)
C-suite (242)
Cystic fibrosis (105)
Data (2122)
Decentralized trials (2)
Denatured (27)
Depression (49)
Diabetes (267)
Diagnostics (6414)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (126)
Drug pricing (106)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87662)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115606)
Executive appointments (724)
FDA (17653)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (767)
Gene editing (109)
Generative AI (20)
Gene therapy (313)
GLP-1 (742)
Government (4497)
Grass and pollen (4)
Guidances (51)
Healthcare (19143)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2786)
Inflammatory bowel disease (140)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (94)
Interviews (311)
IPO (16784)
IRA (43)
Job creations (3700)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (491)
Leadership (17)
Legal (7985)
Liver cancer (73)
Lung cancer (315)
Lymphoma (148)
Machine learning (5)
Management (58)
Manufacturing (302)
MASH (66)
Medical device (13504)
Medtech (13509)
Mergers & acquisitions (19748)
Metabolic disorders (702)
Multiple sclerosis (79)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (32)
Neuroscience (1975)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2606)
Now hiring (39)
Obesity (381)
Opinion (223)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (230)
Patient recruitment (105)
Peanut (47)
People (58636)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21262)
Phase II (29869)
Phase III (22094)
Pipeline (1157)
Policy (140)
Postmarket research (2601)
Preclinical (9077)
Press Release (67)
Prostate cancer (103)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (398)
Real estate (6015)
Recruiting (66)
Regulatory (22692)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (136)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2250)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (30)
The Weekly (47)
United States (22915)
Vaccines (690)
Venture capitalists (42)
Weight loss (252)
Women's health (36)
Worklife (16)
Date
Today (183)
Last 7 days (558)
Last 30 days (2510)
Last 365 days (33889)
2025 (9931)
2024 (36302)
2023 (41015)
2022 (52281)
2021 (56767)
2020 (54924)
2019 (47421)
2018 (35699)
2017 (33029)
2016 (32356)
2015 (38399)
2014 (32187)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39211)
Australia (6527)
California (6011)
Canada (1973)
China (512)
Colorado (265)
Connecticut (278)
Delaware (141)
Europe (85660)
Florida (874)
Georgia (203)
Idaho (57)
Illinois (536)
India (25)
Indiana (309)
Iowa (11)
Japan (157)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (888)
Massachusetts (4574)
Michigan (218)
Minnesota (389)
Mississippi (2)
Missouri (81)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1709)
New Mexico (30)
New York (1704)
North Carolina (1014)
North Dakota (7)
Northern California (2606)
Ohio (202)
Oklahoma (14)
Oregon (37)
Pennsylvania (1339)
Puerto Rico (11)
Rhode Island (33)
South America (1110)
South Carolina (21)
South Dakota (1)
Southern California (2250)
Tennessee (100)
Texas (894)
Utah (176)
Virginia (145)
Washington D.C. (63)
Washington State (562)
West Virginia (3)
Wisconsin (52)
713,690 Results for "acer therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Zevra Therapeutics, Inc. today announced the completion of its acquisition of Acer Therapeutics Inc.
November 20, 2023
·
11 min read
Business
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
RELIEF THERAPEUTICS Holding SA (SWX:RLF), (OTCQB:RLFTF, RLFTY) (Relief Therapeutics) today announced it has entered into a new exclusive definitive licensing agreement with Acer Therapeutics Inc. (Acer Therapeutics) for the development and commercialization of OLPRUVA™ (sodium phenylbutyrate, ACER-001) for the treatment of certain urea cycle disorders (UCDs) and other potential indications.
August 30, 2023
·
6 min read
Deals
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
Zevra Therapeutics, Inc. and Acer Therapeutics Inc. announced the companies have entered into a definitive agreement pursuant to which Zevra would acquire Acer in a merger transaction having a total potential value for Acer stockholders of up to $91 million.
August 31, 2023
·
21 min read
Business
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Acer Therapeutics Inc. reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
August 14, 2023
·
9 min read
Genetown
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
Acer Therapeutics Inc. (Nasdaq: ACER) today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia (Geographical Europe).
August 30, 2023
·
7 min read
Genetown
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Acer Therapeutics Inc. (Nasdaq: ACER) today announced an update on progress in support of its commercial launch of OLPRUVA™ (sodium phenylbutyrate) for oral suspension, including drug availability now expected earlier than anticipated in mid-June 2023, subject to additional capital.
May 1, 2023
·
7 min read
Drug Development
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
Acer Therapeutics Inc. today announced the initiation of two Phase 2, single-arm investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate.
January 5, 2023
·
8 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women
Acer Therapeutics Inc. (Nasdaq: ACER) today announced that topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant).
March 17, 2023
·
6 min read
Genetown
Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder
Acer Therapeutics Inc. today announced the expansion of ACER-801 (osanetant) into a new indication, for the reduction of the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).
October 5, 2022
·
7 min read
1 of 71,369
Next
